Health & Fitness
WALTHAM, Mass.--([ BUSINESS WIRE ])--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that it will host a conference call at 8:00 am ET on Friday, March 30, 2012 to discuss the two releases issued by the Company earlier today:
- The announcement of positive results in the trastuzumab emtansine (T-DM1) EMILIA Phase III trial; and
- The announcement of initiation of Phase II evaluation of IMGN901.
To access the live call by phone, dial 913-312-0982. Passcode is 8250254. The call also may be accessed through the Investor Information section of the Company's website, [ www.immunogen.com ]. Following the live webcast, a replay of the call will be available at the same location through April 6, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGenas collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at [ www.immunogen.com ].